Bone Health Technologies

Bone Health Technologies commercializes Osteoboost, a prescription wearable device that uses precision vibration therapy to reduce bone density loss in postmenopausal women with osteopenia. The company's website states the device is FDA-cleared and clinically proven to slow loss of bone strength and density in the spine and hip.

Osteoboost is marketed as FDA-cleared, which is the regulatory pathway for Class II medical devices, not the more rigorous premarket approval (PMA) required for Class III devices like implantable bone stimulators. The company claims its device is the first FDA-cleared wearable therapy specifically for osteopenia.

The firm sells its Osteoboost device directly to consumers with a valid prescription. The website does not disclose pricing tiers, insurance reimbursement status, or any institutional sales channels. Their commercialization model appears to blend direct-to-consumer outreach with partnerships for clinical education, such as their webinar collaboration with Midi Health.